Avid Bioservices Inc (CDMO)

[nuke661]

geo,

If I remember correctly it was for the reason that FTM stated. They chose not to include squamous not because Bavi was ineffective on squamous cell tumors, it was because the nature of the tumors for squamous are typically/mostly/almost always(??) associated with locations adjacent to/surrounding major arteries and/or veins. This characteristic causes higher risk for treatments that effect the blood supply to tumors, the way Bavi and Avastin do, because these types of treatments are known to have caused harmful bleeding reactions during treatment for these types of tumors. Its as FTM said, it was to reduce the risk of adverse events occurring in the trial. I'm doing this from memory but it lines up with what FTM said.